Aeglea BioTherapeutics Receives $12,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=3f6aa5d0-fc91-462b-939a-29d701bf8586 - Date
1/13/2014 - Company Name
Aeglea BioTherapeutics - Mailing Address
815-A Brazos St. Austin, TX 78701 - Company Description
Aeglea BioTherapeutics is a Texas based start up developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$12,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Undisclosed
